Rampant dissatisfaction with psoriasis drugs: study

Share this article:
Rampant dissatisfaction with psoriasis drugs: study
Rampant dissatisfaction with psoriasis drugs: study

A new study should give antirheumatic drug manufacturers pause. Researchers found that 52.3% of patients with psoriasis and 45.5% of those with psoriatic arthritis are dissatisfied with their treatment.

Their displeasure has had consequences. Of the 1,900 respondents with severe psoriasis, between 9% and 30% said they were not treating their disease—depending on the year, the researchers wrote in JAMA Dermatology. Among those with mild psoriasis, the untreated registered in even greater numbers, ranging from 36% to 49% of patients, while patients with moderate psoriasis fell somewhere in between, at 23% to 45% untreated.

Non-treatment and under-treatment of patients with psoriasis and psoriatic arthritis remains a significant problem in the United States, researchers concluded. "While various treatment modalities are available for psoriasis and psoriatic arthritis, widespread treatment dissatisfaction exists,” they wrote.

As for their reasons, among patients who discontinued biologic treatments in 2008, 25% said the therapy did not work, 17% reported a negative side effect, and 5% said their insurance would not adequately cover the costs of the treatment. An older study had found about 30% of those eligible for a biologic remain untreated due to injection fears.

Among those receiving treatment, 21.5% with severe psoriasis were only treated with topical agents, compared to 29.5% with moderate psoriasis. Methotrexate was cited as the most commonly used oral agent.

It's not so clear that all the patient discontent is influencing the prescription pad, however. Biologics Humira and Enbrel, both of which are approved for psoriasis, were the two top-selling rheumatology drugs in the US for 2012. Humira, sold by AbbVie, posted sales of $4.4 billion, up 28% vs. 2011, according to company-reported data, while Amgen's Enbrel generated sales of $4.3 billion, up 14% year-on-year, according to IMS Health.

Nevertheless, researchers recommended “efforts in advocacy and education…to ensure that effective treatments are accessible to this patient population.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...